CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 72 target
Drug / intervention
Fispemifene (once daily for 8 weeks)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00415571
NCT00415571Phase 2Completed
CompareCT.gov

Efficacy and Safety of Fispemifene in the Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive to PDE5 Inhibitors: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study

QuatRx Pharmaceuticals Company·interventional·Posted Dec 25, 2006·Updated Feb 3, 2010

In Brief

A Phase 2 clinical trial evaluating Fispemifene (once daily for 8 weeks) for Hypogonadism and Erectile Dysfunction. Completed, enrolled 72 participants across 14 sites.

Detailed Summary

The objective of the study is to assess and compare the preliminary efficacy, safety and tolerability of fispemifene 300 mg and placebo given once daily for 8 weeks in the treatment of hypogonadal men with erectile dysfunction (ED) unresponsive to PDE5 inhibitors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism, Erectile Dysfunction
CountriesUnited States
CollaboratorsHormos Medical

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 25, 2006
Enrollment StartDec 1, 2006
Study CompletionAug 1, 2008
TodayJul 2, 2026
Posted 19.5 years ago

Interventions

Fispemifene (once daily for 8 weeks)drug